Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Who Met Severity Classification III

NCT00415519 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

25

Enrollment

INDUSTRY

Sponsor class

Conditions

Amyotrophic Lateral Sclerosis (ALS)

Interventions

DRUG: MCI-186
DRUG: Placebo of MCI-186

Sponsor

Tanabe Pharma Corporation